ArticleJournal for immunotherapy of cancer2022

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.

Jeong A Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.